Theravance Biopharma, Inc. (TBPH)
NASDAQ: TBPH · Real-Time Price · USD
8.62
+0.02 (0.29%)
Apr 17, 2025, 4:00 PM EDT - Market closed
Company Description
Theravance Biopharma, Inc., a biopharmaceutical company, develops and commercializes of medicines in the United States.
It offers YUPELRI, a once-daily, nebulized long-acting muscarinic antagonist for the treatment of chronic obstructive pulmonary disease (COPD).
The company’s product includes Ampreloxetine, an investigational norepinephrine reuptake inhibitor that has completed Phase III study for neurogenic orthostatic hypotension; and TRELEGY for the treatment of COPD and asthma.
It has a strategic collaboration agreement with Viatris Inc. for the development and commercialization of revefenacin, including YUPELRI.
Theravance Biopharma, Inc. was incorporated in 2013 and is based in South San Francisco, California.
Theravance Biopharma, Inc.
| Country | United States |
| Founded | 2013 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 97 |
| CEO | Rick Winningham |
Contact Details
Address: 901 Gateway Boulevard South San Francisco, California 94080 United States | |
| Phone | 650-808-6000 |
| Website | theravance.com |
Stock Details
| Ticker Symbol | TBPH |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001583107 |
| CUSIP Number | G8807B106 |
| ISIN Number | KYG8807B1068 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Rick E. Winningham M.B.A. | Chief Executive Officer and Director |
| Aziz Sawaf C.F.A. | Senior Vice President and Chief Financial Officer |
| Stuart Knight | Senior Vice President of IT&I and Chief Information Officer |
| Brett A. Grimaud Esq. | Senior Vice President, General Counsel and Secretary |
| Rhonda F. Farnum | Chief Business Officer and Senior Vice President of Commercial and Medical Affairs |
| Stacy L. Pryce | Senior Vice President and Chief Strategy Officer |
| Dr. Aine Miller Ph.D. | Senior Vice President of Development and Head of Ireland Office |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 10, 2025 | DEF 14A | Other definitive proxy statements |
| Mar 7, 2025 | 10-K | Annual Report |
| Feb 26, 2025 | 8-K | Current Report |
| Feb 14, 2025 | SCHEDULE 13G/A | Filing |
| Jan 21, 2025 | 144 | Filing |
| Nov 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Nov 14, 2024 | 10-Q | Quarterly Report |
| Nov 12, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Nov 12, 2024 | 8-K | Current Report |
| Nov 4, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |